Beacon Therapeutics的动态

Global multi cancer early detection market size is expected to reach $2.93 Bn by 2028 at a rate of 19.2%, segmented as by type, liquid biopsy, gene panel, laboratory developed tests (ldt), other types For more Info: https://lnkd.in/gGUQRJGW #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Want to hear more about negotiating cell and gene therapy deals? We’ve got a great panel line up on 5 June so do sign up to hear more about their experiences when CGT licensing and collaboration agreements, investment rounds and more. I’m really looking forward to chairing this discussion! ?????? #bristowsllp, #onenucleus, #cellandgene, #intellectualproperty, #lifesciences

Asuragen, a Bio-Techne brand has established the market-leading technology for the reliable amplification and analysis of CGG triplet repeats in the FMR1 gene. The AmplideX?PCR/CE C9orf72 Kit (RUO) is an expansion of this technology into the?neurogenetics space. The kit provides?clinical and pharmaceutical researchers with a reliable and reproducible method for high-resolution genotyping of hexanucleotide repeat expansions in the?C9orf72 gene, which is of increasing?interest in frontotemporal dementia (FTD) – the second most common form of early onset dementia after #Alzheimers Disease – and amyotrophic lateral sclerosis (ALS). Learn more: https://lnkd.in/ebKsEAHB

?? Mark your calendars! Our first webinar in the 2024 series by eXmoor Pharma kicks off in September. Dive deep into CMC strategies for Cell & Gene Therapy and ensure your pathway from lead to launch is seamless. Register now! https://buff.ly/4dWVyMS #Pharma #CGT #WebinarSeries

#Cardiometabolic risk factors are still among the leading drivers of both global mortality and morbidity. Over the past 5 years, the number of clinical-stage cardiometabolic assets has increased by 13%, and today, it accounts for 7% of the overall industry R&D pipeline. This includes cell, gene and RNA therapeutics. Explore the latest trends in cardiometabolic breakthroughs, the market opportunity, and critical success factors for innovators. Download the white paper to learn more: https://bit.ly/3ZeOCWf #obesity #clinicaltrials

Navigating the regulatory pathway from discovery to the clinic for CRISPR-based therapeutics is a complex and multifaceted process. Download our free whitepaper which guides you through the intricate regulatory voyage of CRISPR based cell and gene therapies and expedite your way to success. Our newly released whitepaper discusses: ?? Key regulatory milestones in the CGT drug development process ?? Vital considerations at each developmental phase, complete with guidelines and resources ?? A clear breakdown of the IND filing, FDA review, and approval process Download here: https://ow.ly/pM6b50ReHYy #whitepaper #CRISPR #cellandgenetherapy #clinicresearch #cancertherapy #therapeutics

Heading to ASGCT in Baltimore? Come get your groove on at booth #730 or check out our talk to learn how Stunner and Leprechaun can help you bust through bottlenecks in your gene and cell therapy workflows! #ASGCT2024!

2 Cardiac related clinical studies (Phase 1 & Phase 3) published today in NEJM Firstly, CRISPR-Cas9 Gene Editing (one time treatment)?from Intellia Therapeutics in Phase 1 for Transthyretin amyloidosis with cardiomyopathy (ATTR-CM). In 36 patients over a period of 12 months showed TTR level went down by 90% (whereas Alnylam have shown 81%) https://lnkd.in/gCMuNGm5 Secondly, Tirzepatide (GLP-1 aka silver bullet) from Eli Lilly in Phase 3 for heart failure with preserved ejection fraction (HFpEF). In 731 patients over a period of ~12 months showed 38% reduction of HF hospitalization, diuretic intensification, or CV death. https://lnkd.in/gdXzQEVd

If you're excited for a fantastic science meal at #ESGCT2024 in #Rome, don't forget to save room for dessert! Peter Cabeceiras will give an oral presentation during the last session of the ESGCT meeting on DLVR-M a novel virus-like particle developed at Nvelop Therapeutics We will share our preliminary data showing that this particle can be fully humanized, can accommodate a variety of editing cargos for #invivo #genetherapy, including #CRISPR Base and Prime editors, and can achieve high efficiency of multiplex #geneediting in therapeutic relevant loci in resting #hematopoietic #stemcells. Title: DLVR-M: a novel fully humanized particle for the efficient in vivo delivery of large gene-editing cargoes to human cells. Date/Time: Friday, October 25, 11:00 a.m. – 1:00 p.m. CEST Abstract #OR106 Session room: Meeting room 2 See you there!!

Precision and patient-focus are key for cell, gene and immunotherapy clinical studies. At Advanced Clinical, our team understands the complexities of these trials. Learn how our team can make sure your immunotherapy study is set up for success: https://hubs.la/Q02z-3Vm0 #Immunotherapy #CellGeneTherapy #CellTherapy #GeneTherapy #ClinicalTrials